Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients
Status:
Unknown status
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
The French intensive care societies (SRLF and SFAR), in agreement with the European and
American societies for enteral and parenteral nutrition, recommend to quickly administer an
artificial nutrition to patients admitted to ICU and for which it is expected that they will
not be able to eat normally in the three days of admission.
Enteral nutrition should be used in priority if the gut is functioning. However, intolerance
to enteral nutrition, such as vomiting, regurgitation, increased residual gastric volume, or
diarrhea, occurs in 40% of patients hospitalized in ICU receiving enteral nutrition.
Intolerance to enteral nutrition leads to the risk of not receiving enough nutrition. Feeding
intolerance also exposes to the risk of acute mesenteric ischemia, especially in the most
severe patients under catecholamine for shock. Currently, it is not possible to predict
intolerance to enteral nutrition in ICU patients. Thus, the diagnosis of intolerance is made
a posteriori while enteral nutrition is in progress.
Citrullinemia (normal concentration of 20 to 60 μmol / L), could be a good biomarker of the
function of enterocytes involved in the absorption of food.
The aim of this study is to evaluate the interest of citrullinemia to predict tolerance to
enteral nutrition in ICU patients.